One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20%. Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advan ...

Boehringer Ingelheim will present the latest data in its robust oncology pipeline at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including patient-reported outcomes (PRO) ...

A new large analysis led by American Cancer Society (ACS) researchers shows engaging in leisure-time moderate-to-vigorous ...